Search
Vortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalreceptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. … More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: KELAC® 20 MG, BRINTELLIX® 20 MGLeflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous.
Synonyms: 4-ISOXAZOLECARBOXAMIDE, 5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MGEthinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigational[A191107] Ethinylestradiol was granted FDA approval on 25 June 1943.[L11884]
Mixtures: DONABELLA® 2 MG /0.035 MG, DONABELLA® 2 MG /0.035 MGCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2
go.drugbank.com/bio_entities/BE0000059TargetEnzymeHumans3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system plays a crucial role in the biosynthesis o...
Polypeptides: 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2Putative 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase
go.drugbank.com/bio_entities/BE0023607EnzymeHumansCatalyzes the stereoselective decarboxylation of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) to (S)-allantoin, a step in the uric acid degradation pathway following urate oxidation (By similarity
Polypeptides: Putative 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylaseSynonyms: Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylaseEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MGAcitretin
go.drugbank.com/drugs/DB00459ApprovedInvestigationalIt is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Synonyms: (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid, all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acidProducts: Keracutan 25 mg Kapseln, NEOTIGASON (25 MG CAPSULE)Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: BETMIGA 25 MG, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADADe Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
smpdb.ca/view/SMP0024316MetabolicThe enzyme 1-acyl-sn-glycerol-3-phosphate acyltransferase converts LPA into phosphatidic acid (1,2-diacyl-sn-glycerol 3-phosphate) by esterifying an acyl-group to the sn-2 position of the glycerol backbone